
AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

Bispecific IgG switch off SARS-CoV-2 escape variants
The team headed by Daniel Ruzek or Luca Varani from the University of Bellinzona and the Czech Academy of Sciences targeted two binding sites within...

Italian Enthera Pharma raise €35m in Series A extension
Roche Venture Fund joined seed investor Sofinnova Partners and AbbVie Ventures and co-investors including the JDRF T1D Fund, an investor group...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...